NASDAQ:NTLA
Intellia Therapeutics
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.intelliatx.comipo date
May 06, 2016
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxa...Show More
Earnings
Earnings Release in 5 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus